10-Q: Cryo-Cell Q3 2025: Revenue Dip, Duke Dispute Escalates

Sentiment:

Quarterly Report 15 October 2025 5:00 PM

📋All filings for Cryo Cell International INC

Cryo-Cell International reports a decrease in Q3 2025 revenue and net income, alongside escalating legal disputes with Duke University impacting future growth plans.

Delay expectedThe opening of the Cryo-Cell Institute for Cellular Therapies is on pause indefinitely, having been previously anticipated for Q4 2021, Q1 2022, and then Q4 2024.The proposed spinoff of Celle Corp., a wholly-owned subsidiary, is on hold.Expansion into cord blood and cord tissue infusion clinic services and biopharmaceutical manufacturing through the Duke License Agreement is unlikely and on pause due to the dispute.

Capital raiseThe company may require capital to fund startup expenses for its planned infusion clinic, finance clinical trials related to the Duke License Agreement, develop biopharmaceutical manufacturing capabilities, and cover capital expenditures for software enhancements and equipment.Previously, over $50 million was anticipated to be needed over the next 5 years for Duke-related activities, but current funding needs are unpredictable due to the arbitration.Potential funding sources include cash-on-hand, future operating cash flows, the revolving line of credit, and potential additional debt or equity sales.There are no assurances that additional debt or equity financing will be obtained on favorable terms or at all.

Worse than expectedNet income decreased significantly for both the three and nine months ended August 31, 2025, compared to the prior year periods.Total revenue declined, driven by a notable decrease in new domestic cord blood specimens processed and a substantial drop in public cord blood banking revenue.The company recorded losses on marketable securities, contrasting with gains in the previous year, impacting overall profitability.Cash and cash equivalents saw a significant reduction, indicating a tightening of liquidity.Increased legal fees contributed to higher selling, general and administrative expenses for the nine-month period, reflecting the costs of ongoing disputes.

Summary

Total revenue for the three months ended August 31, 2025, was $7,825,432, a 3% decrease from $8,066,715 in the same period of 2024.
Total revenue for the nine months ended August 31, 2025, was $23,723,155, a 1% decrease from $23,961,761 in the same period of 2024.
Net income for the three months ended August 31, 2025, was $749,408, down from $1,051,679 in Q3 2024.
Net income for the nine months ended August 31, 2025, was $1,388,048, down from $2,263,710 in 9M 2024.
Processing and storage fee revenue saw a 3% increase in recurring annual storage fees for 9M 2025, but this was offset by a 14% decrease in new domestic cord blood specimens processed.
Public cord blood banking revenue significantly decreased to $4,119 for Q3 2025 (from $120,609 in Q3 2024) and to $128,886 for 9M 2025 (from $205,799 in 9M 2024) due to customer demand volatility.
Cost of sales decreased by 11% for 9M 2025 and 15% for Q3 2025, primarily due to the decrease in new domestic cord blood specimens processed.
Selling, general and administrative expenses increased by 2% for 9M 2025 to $12,772,301, driven by a $604,000 increase in legal fees related to ongoing legal proceedings.
Research, development and related engineering expenses decreased significantly to $291,479 for 9M 2025, with no funding for the Duke IMPACT Study in the current period.
The company recorded losses on marketable securities of $193,886 for Q3 2025 and $604,619 for 9M 2025, contrasting with gains in the prior year periods.
Cash and cash equivalents decreased to $265,207 at August 31, 2025, from $560,960 at November 30, 2024.
Duke University issued a notice of termination of the Patent and Technology License Agreement effective May 17, 2025.
The company filed an arbitration demand against Duke University on October 4, 2024, alleging fraudulent inducement and breach of contract, seeking over $100 million in damages. Duke has asserted counterclaims.
Expansion plans, including the Cryo-Cell Institute for Cellular Therapies and the spinoff of Celle Corp., are on pause due to the Duke dispute.

Sentiment

Score: 3

Explanation: The significant decline in net income and new specimen processing, coupled with the termination of the Duke License Agreement and the ongoing, high-stakes arbitration, creates substantial uncertainty and negatively impacts the company's growth prospects and financial stability. While operating income improved and a lawsuit was dismissed, the core business challenges and the Duke dispute overshadow these positives.

Positives

Operating income increased to $1,900,536 for the three months ended August 31, 2025, compared to $1,389,890 in the prior year period.
Operating income increased to $4,449,181 for the nine months ended August 31, 2025, compared to $3,602,631 in the prior year period.
Recurring annual storage fee revenue increased by 3% for the nine months ended August 31, 2025.
Cost of sales decreased by 11% for the nine months ended August 31, 2025, and 15% for the three months ended August 31, 2025, indicating some cost management.
Research, development and related engineering expenses decreased significantly, reflecting a reduction in spending in this area.
The class action lawsuit, Lindsey Lehr v. Cryo-Cell International, Inc., was dismissed with prejudice on September 5, 2025, resolving a legal contingency.

Negatives

Total revenue decreased by 3% for the three months and 1% for the nine months ended August 31, 2025, compared to the prior year periods.
Net income decreased significantly by 28.7% for the three months and 38.7% for the nine months ended August 31, 2025, compared to the prior year periods.
New domestic cord blood specimens processed decreased by 11% for Q3 2025 and 14% for 9M 2025, indicating a decline in new business acquisition.
Public cord blood banking revenue saw a substantial decrease of 96.6% for Q3 2025 and 37.4% for 9M 2025, attributed to customer demand volatility.
Selling, general and administrative expenses increased by 2% for 9M 2025, primarily due to a $604,000 increase in legal fees related to the Duke arbitration.
The company recorded losses on marketable securities of $193,886 for Q3 2025 and $604,619 for 9M 2025, a reversal from gains in the prior year periods.
Cash and cash equivalents decreased by $295,753 during the nine months ended August 31, 2025, indicating a reduction in liquidity.
Duke University issued a notice of termination of the Patent and Technology License Agreement effective May 17, 2025, severely impacting the company's strategic expansion plans.
The ongoing arbitration with Duke University, seeking over $100 million in damages, introduces significant legal and financial uncertainty, with a final hearing scheduled for April 2026.
The company paid substantial cash dividends totaling $3,231,227 during the nine months ended August 31, 2025, despite declining cash reserves and net income.

Risks

Uncertainty exists regarding the ability to maximize shareholder value through a strategic transaction or the successful spinoff of Celle Corp., due to the Duke dispute and the need for third-party consents.
The company's common stock may be delisted from NYSE American LLC if it fails to comply with continued listing standards, which could depress stock price and limit liquidity.
Additional capital may be required, especially for activities related to the Duke License Agreement if investments resume, with no assurance of obtaining favorable debt or equity financing on acceptable terms or at all.
The business may decline or grow more slowly than expected, as success depends on widespread market acceptance of stem cell cryopreservation, which is not assured.
Rapid technological and therapeutic changes could render current stem cell uses or equipment obsolete, requiring significant and costly modifications.
Failure to successfully or profitably manufacture and store Mesenchymal Stromal Cells (MSCs), including due to negative clinical trial results, poses a risk.
Clinical development for public blood bank research involves expensive, complex, and lengthy clinical testing, subject to various regulations and high attrition rates.
Inability to obtain regulatory approval for product candidates would negatively impact revenue generation from such products.
The stem cell preservation market is increasingly competitive, with competitors potentially having greater financial resources, making growth and business maintenance more difficult.
A failure in the performance of cryopreservation storage facilities or systems, including those of Duke, could damage stored specimens, lead to litigation, and harm the company's business and reputation.
Systems and operations are vulnerable to damage or interruption from natural disasters, equipment failure, or security breaches, for which redundant systems or formal disaster recovery plans may be insufficient.
The company's future success depends on its ability to retain key personnel and attract, retain, and motivate qualified new personnel, which is challenging in a competitive market.
Operations and performance are significantly dependent on global and regional economic conditions, including inflation, recession, and interest rates, which could adversely affect demand and liquidity.
The outcome of the Duke Arbitration Demand is uncertain, and an unfavorable resolution could negatively and materially impact the company's business, financial position, and results of operations.
There is no assurance that the company will be able to recoup all or any of its damages or investment related to the Duke License Agreement from the arbitration.
Failure to obtain and maintain necessary domestic regulatory registrations, approvals, and compliance with ongoing regulations (e.g., FDA, state licensing) could prevent the company from marketing its services.
Substantial amounts may be required to comply with legislative and regulatory initiatives relating to patient privacy, such as HIPAA and the HITECH Act, potentially leading to penalties for non-compliance.
Failure to comply with laws related to hazardous materials could lead to liability, increased costs, and adverse effects on the business.
International operations are subject to risks including intellectual property protection challenges, unfavorable local laws, political/economic instability, trade disputes, currency fluctuations, and compliance with laws like the Foreign Corrupt Practices Act (FCPA).
Information systems are critical, and failures or significant data security breaches could lead to loss of information, litigation, reputational damage, and operational interruptions.
Increasing use of social media by the company or its employees could give rise to liability, data security breaches, or reputational damage.
The use of open source software in products may pose risks to proprietary software, potentially requiring costly re-engineering or making source code freely available.
Operating as a public company incurs significant costs and demands, including compliance with Sarbanes-Oxley, Dodd-Frank, and NYSE listing requirements.
Failure to maintain an effective system of internal control over financial reporting could adversely affect investor confidence and stock value.
Limitations on the effectiveness of controls mean that not all errors or acts of fraud may be prevented or detected.
Increasing scrutiny and changing expectations from investors, customers, and governments regarding Environmental, Social, and Governance (ESG) policies and practices may lead to additional costs or risks.
Principal stockholders and management own a significant percentage of voting stock, enabling them to exert significant control over matters subject to stockholder approval.
The company may become subject to securities class action litigation, which can be expensive, divert management attention, and expose it to significant liabilities.
As a smaller reporting company, reduced disclosure and governance requirements may make its common stock less attractive to investors.
Indemnification of officers and directors could result in substantial expenditures that the company may be unable to recoup.
Certain provisions of the company's charter, bylaws, and Delaware law (Section 203 DGCL) may delay, defer, or prevent tender offers or takeover attempts.

Future Outlook

The company's strategic expansion plans into cord blood and cord tissue infusion clinic services, biopharmaceutical manufacturing, and the opening of the Cryo-Cell Institute for Cellular Therapies are currently on pause due to the ongoing arbitration with Duke University. The proposed spinoff of Celle Corp. is also on hold. The company anticipates that its existing cash, marketable securities, and cash flows from operations, along with external capital sources, will be sufficient to fund known cash needs for at least the next 12 months. However, funding needs for Duke-related activities are currently unpredictable, and securing additional debt or equity financing on favorable terms is not assured.

Management Comments

"We have based these forward-looking statements on our current expectations, assumptions, estimates and projections."
"We intend to maximize our growth potential through our superior quality, value-driven competitive leadership position, product differentiation, an embedded client base, increased public awareness and accelerated market penetration."
"The Company believes it offers the highest quality, highest value service targeted to a broad base of the market."
"The Company believes that the market for cord blood stem cell preservation is enhanced by global discussion on stem cell research developments and the current focus on reducing prohibitive health care costs."
"It is possible, however, that there could be an unfavorable outcome or resolution of the claims asserted (inclusive of the claims the Company asserts against Duke and the counterclaims Duke asserts against the Company), which could negatively and materially impact the Company’s business, consolidated financial position and results of operations."

Industry Context

The company operates in the dynamic stem cell preservation and cellular therapy industry, which is characterized by rapid technological and therapeutic advancements. While stem cell transplants are accepted treatments for numerous diseases, market penetration for private cord blood banking remains relatively low due to cost perceptions and lack of awareness. The company aims to leverage its cryopreservation expertise to offer third-party cold storage services (ExtraVault) to biopharmaceutical and healthcare institutions. However, the significant dispute with Duke University has stalled its planned expansion into new cellular therapy services and biopharmaceutical manufacturing, which are key growth vectors within the broader regenerative medicine sector.

Comparison to Industry Standards

The company's facility maintains cGMPand cGTP-compliant status with AABB and FACT accreditation, indicating adherence to high industry quality and operational standards.
The company claims its processing method offers superior technology for maximum stem cell recovery and red blood cell depletion compared to other methods.
It reports a 100% viability rate of its specimens upon thaw for therapeutic use since inception, a strong indicator of quality in cryopreservation.
The company's public cord blood units are listed on the National Marrow Donor Program (NMDP) registry, connecting them to major international registries and facilitating distribution to transplant centers worldwide.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Accounting Standard Update	The company is evaluating the impact of ASU 2023-07, 'Enhanced Segment Reporting,' which mandates more detailed disclosures regarding segment expenses, effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024.	2024-12-15	Will require more detailed segment disclosures in financial statements.
Accounting Standard Update	The company is assessing the impact of ASU 2023-09, 'Improvements to Income Tax Disclosures,' which enhances income tax disclosure requirements, effective for fiscal years beginning after December 15, 2024.	2024-12-15	Will require more detailed information on tax rate reconciliation, tax liabilities, and changes in unrecognized tax benefits.
Anti-takeover Provisions	The company's certificate of incorporation, bylaws, and Delaware law (Section 203 DGCL) contain provisions designed to delay, defer, or discourage hostile takeovers, including blank-check preferred stock, advance notice requirements for stockholder actions, and limitations on who may call stockholder meetings.	N/A	Could inhibit temporary fluctuations in stock price from takeover attempts and prevent changes in management, potentially not aligning with all stockholders' best interests.

Legal Proceedings

**Lindsey Lehr v. Cryo-Cell International, Inc.**: A class action complaint filed on January 6, 2023, alleging misrepresentation of service value. The case was removed to federal court, and arbitration was compelled. The plaintiff dropped class action allegations on January 18, 2024. On September 5, 2025, both parties filed stipulations to dismiss the arbitration and court proceedings with prejudice. The company believes this resolution will not have a material adverse effect on its business or financial position.
**Cryo-Cell International, Inc. v. Duke University**: The company filed an arbitration demand on October 4, 2024, alleging fraudulent inducement and breach of the Patent and Technology License Agreement, seeking over $100 million in damages. Duke responded with counterclaims on November 18, 2024 (amended March 24, 2025) for breach of the License Agreement and indemnity. Duke also issued a notice of termination of the License Agreement effective May 17, 2025. A final hearing is scheduled for April 2026. The outcome is inherently uncertain and could negatively and materially impact the company's business, consolidated financial position, and results of operations.

Stakeholder Impact

**Shareholders**: Negative impact due to decreased net income, losses on marketable securities, significant cash dividend payments reducing cash reserves, and substantial uncertainty surrounding the Duke dispute and its impact on future growth and potential Celle Corp. spinoff. There is also a risk of stock price decline due to delisting risk and litigation uncertainty.
**Customers**: Core cord blood and cord tissue storage services remain unaffected. However, potential future benefits from new therapies and expanded services are on hold due to the Duke dispute, which could impact long-term value proposition.
**Employees**: Stalled expansion plans (Cryo-Cell Institute, new business units) may limit growth opportunities and career development within the company.
**Creditors (Susser Bank)**: The revolving line of credit was extended, but the company's declining financial performance and ongoing, high-stakes legal dispute could affect future credit terms or availability.

Next Steps

A final hearing on the arbitration with Duke University and Duke's counterclaims is scheduled for April 2026.
The company is evaluating the impact of new accounting standards, ASU 2023-07 (Enhanced Segment Reporting) and ASU 2023-09 (Improvements to Income Tax Disclosures), on its financial statements.
Discretionary capital expenditures of approximately $1,000,000 are anticipated over the next twelve months for equipment and software enhancements.
The company will continue to monitor the Ukrainian-Russian conflict for potential business impact.

Key Dates

Date	Description
1989-09-11	Cryo-Cell International, Inc. incorporated in Delaware.
2005-12-01	Company began providing its customers that enrolled after December 2005 a payment warranty of $50,000.
2011-12-01	The 2012 Equity Incentive Plan became effective.
2012-02-01	The payment warranty was increased to $75,000 for all new clients.
2012-05-01	The Board of Directors approved an amendment to the 2012 Plan to increase the number of shares reserved for issuance to 2,500,000 shares.
2012-06-06	The Board of Directors increased the number of shares authorized for repurchase to up to 3,000,000.
2012-07-10	Stockholders approved the 2012 Equity Incentive Plan at the Annual Meeting.
2015-04-08	The Board of Directors increased the number of shares authorized for repurchase to up to 6,000,000 shares.
2015-06-30	Acquired manufacturing rights to the PrepaCyte CB Processing System.
2016-10-06	The Board of Directors increased the number of shares authorized for repurchase to up to 8,000,000 shares.
2017-06-01	The payment warranty was increased to $100,000 for new clients choosing the PrepaCyte CB premium processing method.
2018-06-01	Acquired substantially all assets of Cord:Use Cord Blood Bank, Inc.
2019-10-01	The Board of Directors approved amendments to the 2012 Plan, ratified by stockholders on November 21, 2019.
2021-02-23	Entered into a Patent and Technology License Agreement with Duke University.
2022-02-04	First Amendment to the Duke License Agreement.
2022-04-08	The Board of Directors adopted the 2022 Equity Incentive Plan and granted 400,000 market-based vesting condition options to David Portnoy, Mark Portnoy, and Oleg Mikulinsky.
2022-07-18	Entered into a Credit Agreement with Susser Bank for a $10,000,000 revolving line of credit and an $8,960,000 term loan facility. Also completed the purchase of a 56,000 square foot facility in Durham, North Carolina.
2022-08-19	The Board of Directors declared a one-time, special cash dividend.
2022-10-03	Stockholders approved the 2022 Equity Incentive Plan and the market-based options granted on April 8, 2022.
2022-12-01	New two-year employment agreements became effective with David Portnoy and Mark Portnoy.
2022-12-23	David Portnoy and Mark Portnoy were awarded signing bonus options (50,000 and 25,000 shares, respectively) exercisable if the company's stock reached $8.00.
2023-01-06	A complaint styled Lindsey Lehr v. Cryo-Cell International, Inc. was filed.
2023-02-17	Second Amendment to the Duke License Agreement.
2023-03-03	Entered into a Clinical Study and Research Agreement with Duke University.
2023-03-14	The company removed the Lindsey Lehr case to the United States District Court for the Southern District of Florida.
2023-03-21	The company moved to compel arbitration and stay the Lindsey Lehr case.
2023-03-27	Entered into an interest rate swap agreement with Susser Bank.
2023-10-10	The Court granted the company's motion to compel arbitration and stayed the Lindsey Lehr case.
2023-10-27	The plaintiff in the Lindsey Lehr case filed a demand for arbitration and statement of claims.
2023-11-30	The company recorded an impairment charge of $13,108,064 for assets associated with the Duke License Agreement.
2024-01-18	The plaintiff in the Lindsey Lehr case filed an amended statement of claims, dropping class action allegations.
2024-02-22	The company formed its wholly-owned Delaware subsidiary, Celle Corp.
2024-03-19	The company filed an answering statement and counterclaim in response to the plaintiff's claims in the Lindsey Lehr case.
2024-03-26	The company's stock price reached above $8.00, causing the market-based vesting condition options granted on December 23, 2022, to vest immediately.
2024-04-15	The company terminated the interest rate swap agreement and recorded proceeds of $228,000.
2024-10-04	The company filed a demand for arbitration against Duke University with the American Arbitration Association.
2024-11-18	Duke University responded to the arbitration demand and asserted counterclaims against the company.
2024-12-12	The company filed an answering statement in response to Duke's counterclaims.
2025-01-24	The Board of Directors declared a cash dividend of $0.25 per share, paid on February 28, 2025.
2025-03-24	Duke University amended its counterclaims against the company.
2025-05-07	The Board of Directors declared a cash dividend of $0.15 per share, paid on May 30, 2025.
2025-05-17	Duke University issued a notice of termination of the License Agreement.
2025-07-08	Seventh Lease Amendment signed, extending the lease for the Oldsmar, FL headquarters to December 31, 2027.
2025-07-15	Susser Bank extended the maturity date of the revolving credit facility to October 16, 2025.
2025-08-31	End of the current quarterly reporting period.
2025-09-05	The plaintiff and the company filed stipulations to dismissal of the Lindsey Lehr arbitration and United States District Court proceeding with prejudice.
2025-10-15	Date of filing of the Form 10-Q.
2026-04-01	Final hearing scheduled for the arbitration with Duke University.

Recommendation

sell

The company faces significant challenges, including declining revenue from new specimen processing and public banking, substantial losses on marketable securities, and increased legal expenses. The termination of the Duke License Agreement and the ongoing arbitration, with Duke seeking counterclaims and the company's expansion plans on hold, introduce immense uncertainty and risk to future growth and profitability. While operating income improved, the overall financial performance and strategic outlook are severely compromised, making the stock a high-risk investment with significant downside potential.

Keywords

Cryo-Cell, stem cell, cord blood, cryopreservation, Duke University, arbitration, SEC filing, 10-Q, financial results, cellular therapy, PrepaCyte CB, ExtraVault, biorepository, Celle Corp, Q3 2025, revenue, net income, legal dispute

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.